IBIO
$2.09-0.06 (-2.79%)
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved C...
Recent News
iBio Touts Bispecific Antibody Strategy for PH-HFpEF, Eyes Development Candidate in Q3
Executives at iBio (NASDAQ:IBIO) outlined the scientific and strategic rationale for a myostatin/activin A bispecific antibody program that the company believes could become a next-generation therapy for heart failure, with an initial focus on pulmonary hypertension associated with heart failure wit
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
iBio (IBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
iBio Insiders Placed Bullish Bets Worth US$655.0k
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
BC-Most Active Stocks
Nu Holdings Ltd. 30,054,902 16.85